Exodus Point Capital Management, LP Aerovate Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $14.7 Billion
- Q2 2024
A detailed history of Exodus Point Capital Management, LP transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 21,723 shares of AVTE stock, worth $59,086. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,723Holding current value
$59,086% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVTE
# of Institutions
95Shares Held
27.5MCall Options Held
185KPut Options Held
129K-
Ra Capital Management, L.P. Boston, MA9.19MShares$25 Million0.23% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$10.2 Million0.35% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$6.1 Million0.56% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.89 Million0.4% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$3.84 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $66.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...